Product NewsSYMPHOGEN’S SUCCESS IN MANUFACTURING CONSISTENT BATCHES OF POLYCLONAL ANTIBODIES FOR CLINICAL TRIALS ATTRACTS NEW USD 25 MILLION INVESTMENT
